Background: Models of propofol pharmacokinetics and pharmacodynamics developed in patients without brain pathology are widely used for target-controlled infusion (TCI) during brain tumour excision operations. The goal of this study was to determine if the presence of a frontal brain tumour influences propofol pharmacokinetics and pharmacodynamics and existing PK-PD model performance. Methods: Twenty patients with a frontal brain tumour and 20 control patients received a propofol infusion to achieve an induction-emergence-induction anaesthetic sequence. Propofol plasma concentration was measured every 4 min and at each transition of the conscious state. Bispectral index (BIS) values were continuously recorded. We used non-linear mixedeffects modelling to analyse the effects of the presence of a brain tumour on the pharmacokinetics and pharmacodynamics of propofol. Subsequently we calculated the predictive performance of Marsh, Schnider, and Eleveld models in terms of median prediction error (MdPE) and median absolute prediction error (MdAPE). Results: Patients with brain tumours showed 40% higher propofol clearance than control patients. Performance of the Schnider model (MdPEpk À20.0%, MdAPEpk 23.4%) and Eleveld volunteer model (MdPEpk À8.58%, MdAPEpk 21.6%) were good. The Marsh model performed less well (MdPEpk À14.3%, MdAPEpk 41.4%), as did the Eleveld patient model (MdPEpk À30.8%, MdAPEpk 32.1%). The first-order rate constant (k e0 ; 0.108 min
commonly used, but were developed from studies in healthy subjects. The use of antiepileptic medication, inflammation, and the adverse effects of elevated intracranial pressure on cerebral blood flow associated with the presence of a brain tumour may influence propofol pharmacokinetics, leading to different drug concentrations than expected in non-tumour patients for the same drug infusion. Additionally, the presence of a tumour, or secondary effects such as local pressure, chemical irritation, inflammation, and oedema, might be associated with altered propofol pharmacodynamics. The tumour-related changes could affect the function of cortical and subcortical neural pathways responsible for consciousness, such that patients with frontal brain tumours might require different propofol concentrations to achieve the same anaesthetic hypnotic effect compared with control patients.
Package inserts issued by a number of pharmaceutical companies recommend propofol dose alterations in neurosurgical patients, but the scientific evidence for this is weak and conflicting. Some studies have indeed shown differential sensitivity to propofol in patients with brain tumours. [5] [6] [7] However, we found no significant differences in propofol dose requirements for loss of consciousness, measured propofol plasma concentrations at loss and return of consciousness, and bispectral index (BIS) values at loss and return of consciousness between patients with frontal brain tumours and control patients. 8 The purpose of the current study was to conduct a more extensive, secondary analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data collected during the course of our previous study. We performed additional analyses using all available data and non-linear mixed-effects modelling to answer the following clinical questions: (1) Is it necessary to adjust the induction and maintenance dose of propofol in patients with frontal brain tumour compared with control patients? (2) How accurate is the predictive performance of established PK-PD models in patients with brain tumours? (3) Are patients with frontal brain tumours more sensitive to the hypnotic effects of propofol?
Methods
This is a secondary analysis of data collected during a previously published study 8 that was approved by the local ethics committee (University Medical Center Groningen Ethics Committee, number 2009058) and registered at ClinicalTrials.gov (NCT01060631). All subjects provided written informed consent and were included between August 2009 and April 2011. All were >18 years of age and were scheduled to undergo an elective neurosurgical procedure. None had neurological, cognitive, sensory, or cardiovascular deficits, which could have potentially interfered with the study protocol. Initially 56 subjects were enrolled; 16 were excluded from further analysis, in most cases because they showed equivocal responses to command at transitions of consciousness, and in a few cases because of technical problems (see consort diagram in the previous article 8 ). This yielded a dataset originating from 20 subjects with frontal brain tumours and 20 control (spinal surgery) subjects.
Study protocol
The clinical protocol has been described previously. 8 Before the operation, a 20G intravenous cannula was inserted and standard monitoring equipment was applied as recommended by the American Society of Anesthesiologists. 9 Bilateral BIS electrodes were applied to the patient's forehead and connected to a BIS VISTA monitor (Medtronic, Minneapolis, MN, USA) to record continuous bilateral BIS values during the study. An arterial cannula was inserted into the radial artery of the patient's non-dominant arm for continuous arterial blood pressure monitoring and frequent arterial blood sampling. Anaesthesia was induced with a fixed rate infusion of propofol 2% (Diprivan, AstraZeneca, London, UK) at 100 ml hr
À1
. During the induction phase, subjects were asked to squeeze their dominant hand every 10 s. These requests were delivered through headphones using a pre-recorded audio track. The infusion continued until loss of responsiveness (LOR 1 ), defined as two consecutive failures to respond to this verbal prompt. Propofol was infused using Alaris Asena syringe pumps (Becton Dickinson, Carefusion, San Diego, CA, USA) controlled by a medical-grade computer programmed with Rugloop II (Demed, Temse, Belgium) software. In addition to controlling the infusion pumps, Rugloop II continuously recorded the following variables: propofol infusion rate (ml h À1 ), cumulative propofol volume (ml), and routinely recorded physiological values. The estimated propofol plasma and effect-site concentrations (C pest and C eest ) were calculated using the Schnider PK model. 3 After LOR 1, the airway was secured, the first arterial blood sample was drawn, the fixed-rate infusion was switched from a fixedrate mode to an effect-site targeted TCI mode (with the estimated effect-site concentration at LOR 1 as the target), and a padded tourniquet was applied to the dominant arm and inflated to 20% above the patient's baseline systolic blood pressure to facilitate the isolated forearm technique as described previously. 10 In order improve the quality of BIS and EEG recording, 0.6 mg kg À1 rocuronium bromide (Fresenius Kabi, Bad Homburg, Germany) was administered. BIS values were recorded electronically every 5 s. During the next 20 min the propofol infusion was continued in effect-site targeting mode at the same target concentration while arterial blood samples were drawn every 4 min. Twenty minutes after LOR 1 the propofol infusion was stopped and subjects were again regularly instructed to squeeze their hand; return of responsiveness (ROR) was defined as two consecutive positive responses. A fixed rate infusion of propofol at 100 ml h À1 was once more started and continued until LOR 2 was determined using the same method used to determine LOR 1 . From LOR 1 and every 4 min thereafter, arterial blood samples were taken for propofol assay. Extra arterial blood samples were taken at ROR 1 and LOR 2 . Arterial blood samples were stored in heparin-coated blood collection tubes. Immediately after completion of the study, samples were centrifuged and plasma was removed and stored at À20 C until assayed. Propofol assay was performed by a certified analyst as described. 8 11 Editor's key points
• Effects of neurological diseases on propofol pharmacokinetics and pharmacodynamics have important implications for its use by target-controlled infusion in neurosurgery.
• Non-linear mixed-effects modelling was used to study the effects of frontal brain tumour pathology on propofol pharmacokinetics and pharmacodynamics.
• Propofol clearance was 40% higher in patients with brain tumours compared with controls, but there were no differences in sensitivity to the drug.
Data analysis
Tumour and control group characteristics and physiological data were tested the using Student's t-test for continuous variables and v 2 test for categorical variables.
Model development
Data were used to generate PK-PD models to understand the differences between patients with and without brain tumours.
For PK-PD model building we used a sequential method. 12 We first constructed a PK model and individual predicted plasma concentrations from the final PK model were used subsequently for the calculation and PD model estimation. Uncertainty in estimated model parameters was evaluated by estimating the upper and lower 95% confidence limits by spline interpolation of the likelihood profiles. We determined what increase/ decrease in each parameter is required to increase the NONMEM objective function by 3.84.
PK model
Propofol plasma concentrations were modelled using two-and three-compartment PK models with volumes V 1 , V 2 , and V 3 ; elimination clearance CL; and intercompartmental clearances Q 2 and Q 3 . PK model parameters were assumed to be either log-normally distributed or constant across the population.
Residual error was assumed to be normally distributed, and for PK, proportional to the predicted propofol concentration and for PD, additive. Hierarchical model building was performed by adding and removing parameters from the model to obtain a good model fit evaluated using the corrected Akaike information criterion (AIC). Covariates age, weight, height, sex, BMI, and presence/ absence of a tumour were tested to identify potentially relevant model parameter relationships by examination of post hoc variability (g) values and subsequently tested for inclusion in the model. Model parameters were calculated relative to a reference individual: 70-kg, 35-year-old, 170-cm male patient. Total body weight (WGT) was used as a size descriptor. The presence/absence of a tumour was modelled as a scalar correction.
PD model
A sigmoidal E max model was used to model BIS. An effect compartment concentration (Ce) was connected to the plasma compartment by a first-order rate constant (k e0 ). Residual error was assumed to be additive. The equations used were
where C and Ce are the concentrations in the central (V 1 ) and effect compartments, BIS baseline is the BIS measure in the absence of propofol, Ce 50 is the Ce associated with 50% of the maximum effect, c is the steepness of the concentration versus response relation, and e represents additive residual error. The time delay for signal processing in the BIS measurement 13 14 was initially estimated from the data as a single value for all individuals.
Evaluation of model performance
Predictive performance of the models was evaluated using the Varvel criteria. 15 For PK observations we calculated the performance error (PE PK ) and absolute performance error (APE PK ) as
For BIS we used performance error calculations more suitable for additive-error models:
Models are often compared based on median prediction error (MdPE PK and MdPE BIS ) and median absolute prediction error (MdAPE PK ) as measures of accuracy and precision. When C predicted or BIS predicted is obtained from the population model, then this describes the performance of the population model to predict the observations. Alternatively, when C predicted or BIS predicted is obtained from individual estimates, then this describes the fit of the individuals to the data, i.e. how close the individual predictions are to the observations. Criteria for a clinically acceptable performance are an MdPE PK of <10-20% and an MdAPE PK between 20 and 40%. 16 17 During model development we included a covariate relationship if it decreased the AIC by at least 3.84, corresponding to a P-value <0.05 for a v 2 distribution with 1 degree of freedom. We additionally required the MdPE PK or MdPE PD to decrease. To gain perspective of the predictive performance of our new PK model, we calculated the predictive performance of the Schnider model, 3 which was used to guide TCI administration in our study, and also the predictive performance of the Marsh 4 and Eleveld 18 PK models. The Eleveld PK model makes the distinction between the PK of patients and volunteers, and we investigated both characterizations.
Results
There were no differences in the characteristics of the tumour and control group subjects. In 40 subjects, a total of 440 propofol concentration measurements were made. One observation from a subject in the tumour group was rejected because it showed an implausibly large increase in concentration even though the infusion had been stopped for some time before the sample.
PK model development
The PK model development process is shown graphically in Figure 1 . Applying allometric scaling to the linear three-compartment model showed a small increase in AIC without changing the number of parameters (Model 9). Similar to the linear PK model, the population variability in V 3 and Q 2 could be removed without degrading the fit of the model (Model 10 and 11). This model also showed increased CL in the tumour group compared with the control group, and including this in the model (Model 12) resulted in an improved model.
Applying compartmental allometry to V 2 /Q 2 and V 3 /Q 3 in the three-compartment allometric model lead to an improved model fit (Model 13). Similar to the linear and allometric models, the population variability in V 3 and Q 2 could be removed without degrading the fit of the model (Model 14) . Again, this model also showed increased CL in the tumour group compared with the control group, and including this in the model (Model 15) resulted in an improved model. For Model 15 we also evaluated the possibility that antiepileptic drugs (AEDs) increased CL in the tumour group due to the induction ofcytochrome P450 activity. Older-generation AEDs such as carbamazepine, phenytoin, phenobarbital, and primidone are known enzyme inducers. 20 In the tumour group, 10 subjects used AEDs, including 2 using enzyme-inducing AEDs. Neither AEDs in general (Model 16) nor enzyme-inducing AEDs (Model 17) were helpful in explaining the higher CL in the tumour group. Overall, the best AIC was for Model 15, the three-compartment PK model with compartmental allometry and higher CL for the tumour group. This model also showed good fit to the individual data, with an individual MdAPE PK of 7.74%. This was selected as the final PK model and was subsequently used to obtain individual predicted propofol concentration estimates for subsequent PD modelling.
The summarized equations for the final PK model are Size ¼ ðWGT=70kgÞ PK model performance evaluation Table 3 shows the predictive performance of the final PK model compared with other propofol PK models from the literature. The better performance of our final PK model is expected because it concerns in-sample predictions, i.e. predictions also used for model estimation, while for the other models these are out-of-sample predictions. The MdAPE PK was lower in the control group for all PK models. Performance for the Schnider and Eleveld (volunteer) models is quite good and well within the margins of clinical acceptability. In contrast, the predictive performance of the Marsh model was unacceptable due to excessive imprecision for both the tumour and control groups and the Eleveld (patients) PK model showed excessive bias for the tumour group. Figure 2 shows the simulated propofol infusion rates necessary to achieve and maintain the propofol plasma concentration of 3 mg ml À1 in a 35-year-old male of 70 kg and height of 170 cm. In order to maintain the same plasma concentration of propofol, the maintenance infusion rate needs to be higher in patients with frontal brain tumours compared with the control patients.
PD model development

Discussion
The main aim of this study was to investigate whether the presence of a frontal brain tumour influences the pharmacokinetics and pharmacodynamics of propofol by performing a secondary, more detailed analysis of data collected in our previous study. 8 Considering the pharmacokinetics, CL was higher in subjects with a brain tumour compared with the control group. This suggests that if the same target propofol concentration is desired, infusion rates should be higher in patients with brain tumours compared to those undergoing spinal surgery (see Fig. 2 ). The presence of AEDs was not useful to predict the increased CL in tumour patients and thus we postulate that other factors are responsible for the observed difference in pharmacokinetics.
Considering the pharmacodynamics, we did not find any difference in propofol k e0 , Ce 50 , or c in patients with and without brain tumours. These findings suggest that patients with brain tumours are not more sensitive to the hypnotic effects of propofol compared with patients without brain tumours. These findings corroborate our previous conclusion 8 but are still in conflict with Chan and colleagues, 5 who concluded that the propofol dose necessary to suppress responses to verbal commands is decreased in patients with large brain tumours compared with small brain tumours. As stated in our previous article, methodological and statistical differences might account for the differing conclusions. Patients in Chan's study had larger brain tumours on average, which were in more heterogeneous locations than those of the patients in our study. Our PD analysis showed that patients in the tumour group have a lower BIS baseline value. This could slightly influence the clinical interpretation of BIS index values, and thus titration of propofol, by creating the impression that less propofol is needed to achieve comparably low BIS values. Despite, or maybe because of, the fact that BIS is one of the most validated hypnotic drug effect monitors available, there are a number of publications describing clinical conditions that affect BIS monitor output. For example, BIS values measured in patients who are in a post-ictal state might not necessarily match the hypnotic state of the patient. 24 In our previous study 8 we found no differences in propofol pharmacokinetics or pharmacodynamics between patients with and without brain tumours. This is different than our current findings. The difference in conclusion regarding pharmacokinetics could be due to the use of NONMEM to construct a full pharmacokinetics model. NONMEM is a 'gold standard' method to analyse PK-PD data 28 and may be more sensitive to detect PK differences compared with the previously applied method determining the average propofol plasma concentration at transitions between consciousness and unconsciousness. The difference in pharmacodynamics could be a result of the different PD measures used. We modelled BIS, while the previous investigation focused on the transitions to and from consciousness.
The main limitation of our study is that our sampling scheme could have been better optimized to fully characterize the pharmacokinetics of propofol. Our primary study was performed right before the start of a surgical procedure and was optimally designed to determine BIS values and propofol arterial plasma concentrations at transitions between consciousness and unconsciousness. Even though the study time was in excess of 1 h, the choice to conduct the study right before the start of an operation inherently limited the possible study length and thus also the steady-state infusion time and the number of steady-state samples as well as the propofol washout time and the possibility of taking late washout samples. This resulted in highly reliable V 1 and V 2 determinations, but less reliable determinations of V 3 and CL, as can be seen in likelihood profiles. Nevertheless, our PK parameters are in general agreement with previous studies 3 18 and, in addition, the prediction performance of our PK-PD model is good. Another limitation of our study is the choice of the control group from patients receiving spinal surgery. Our conclusion is thus not as strong as it would have been had we sampled our control group from a broader patient population. Neither the control nor tumour group received opioids during the study period, since opioids are well known to influence propofol pharmacokinetics and pharmacodynamics.
30
The Eleveld PK model makes a distinction between the pharmacokinetics of patients and volunteers. We found better predictive accuracy for both control and tumour subjects when they were classified as volunteers rather than, perhaps more correctly, as patients. Eleveld suggested that the essential difference between the PK patients and volunteers was due to the use of concomitant medication, especially opioids, in patients. Our finding of better performance when classifying individuals in the current investigation as volunteers supports Eleveld's suggestion that the PK difference between volunteers and patients results from the use of opioids in patients.
In conclusion, we found that maintenance doses, but not induction doses, should be adjusted in patients with brain tumours, due to considerably higher clearance in the latter group; the Marsh model for propofol has a poor predictive performance due to high inaccuracy, while the Schnider and Eleveld volunteer models perform well in predicting pharmacokinetics (and pharmacodynamics); and patients with brain tumours are not more sensitive to the hypnotic effects of propofol, but their initial BIS index values are significantly lower. Handling editor: Hugh C Hemmings Jr
